EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-Resistant Acinetobacter baumannii

Inam Ullah iD, Song Cui, Qiulong Yan, Hayan Ullah, Shanshan Sha, Yufang Ma iD

Antibiotics · 26.09.2025 · 14 (10) · 975

DOI: 10.3390/antibiotics14100975 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 26.09.2025. Verfasst von Inam Ullah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian 116044, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rapid emergence of antibiotic resistance in Acinetobacter baumannii has led the World Health Organization (WHO) to designate it as a “high priority” pathogen. The emergence of multidrug-resistant (MDR) and pandrug-resistant (PDR) strains poses considerable treatment challenges. As antimicrobial resistance (AMR) escalates toward a post-antibiotic era, innovative therapeutic solutions are urgently needed.

Objectives

To clone, over-express, and characterize a novel endolysin, LysTAC1, from Acinetobacter phage TAC1 for its antibacterial efficacy against multidrug-resistant bacteria.

Methods

A 24 kDa endolysin featuring a glycoside hydrolase Family 19 chitinase domain was tested against carbapenem-resistant Acinetobacter baumannii clinical isolates and various Escherichia coli strains following outer membrane permeabilization with Ethylenediaminetetraacetic acid (EDTA). Stability assays and molecular docking studies were performed.

Results

LysTAC1 demonstrated potent lytic activity against Gram-negative bacteria but showed no activity against Gram-positive bacteria (Staphylococcus aureus ATCC 29213 and Enterococcus gallinarum HCD 28-1). LysTAC1 maintained activity across pH 6–9 and temperatures 4–65 °C, with differential sensitivity to metal ions where K+ showed no inhibitory effect at any concentration (0.1–100 mM), and Fe2+ was non-inhibitory at lower concentrations (0.1–1 mM), while Mg2+ and Ca2+ demonstrated concentration-dependent inhibition across the tested range (0.1–100 mM). Molecular docking revealed LysTAC1 interactions with chitinase substrates 4-nitrophenyl N-acetyl-β-D-glucosaminide and 4-nitrophenyl N, N-Diacetyl-β-D-chitobioside, with binding energies of −5.82 and −6.85 kcal/mol, respectively.

Conclusions

LysTAC1 shows significant potential as a targeted therapeutic agent against A. baumannii with robust stability under physiological conditions.

Schlagwörter

Stichwörter der Autor:innen

Acinetobacter baumanniiantibiotic resistanceendolysinexpressionin silico analysis

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian 116044, China.
  • Department of Critical Care Medicine, Dalian Municipal Central Hospital, Central Hospital of Dalian University of Technology, Dalian 116021, China.
  • Department of Microbiology, Dalian Medical University, Dalian 116044, China.

ORCID-Profile: Inam Ullah, Yufang Ma

Zitieren

APA

Ullah, I., Cui, S., Yan, Q., Ullah, H., Sha, S., & Ma, Y. (2025). In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-Resistant Acinetobacter baumannii. Antibiotics, 14(10), 975. https://doi.org/10.3390/antibiotics14100975

Vancouver

Ullah I, Cui S, Yan Q, Ullah H, Sha S, Ma Y. In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-Resistant Acinetobacter baumannii. Antibiotics. 2025;14(10):975. doi:10.3390/antibiotics14100975

BibTeX
@article{Ullah2025,
  author = {Ullah, Inam and Cui, Song and Yan, Qiulong and Ullah, Hayan and Sha, Shanshan and Ma, Yufang},
  title = {In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-Resistant Acinetobacter baumannii},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {10},
  pages = {975},
  doi = {10.3390/antibiotics14100975}
}
Kostenlos starten →